|
Tipton, KS | "Retatrutide, an investigational triple agonist, causes dose-dependent increases in resting heart rate. In clinical trials, higher doses (like 12 mg) elevated heart rates by an average of about 6 to 7 bpm. This elevation typically peaks around week 24 of treatment before declining"
News Conference News ADA 2023
Dramatic Weight Loss, Cardiometabolic Improvement With Retatrutide
June 28, 2023
The once-weekly injectable targeting three hormone receptors hints at “fundamental change” for cardiometabolic disease.
https://www.tctmd.com/news/dramatic-weight-loss-cardiometabolic-impr...
| |
|
Retatrutide drug for weight loss
